Slow Heartbeat: Labs, Diagnosis, and Next Steps

What Bradycardia Actually Means

A heart rate below 60 bpm at rest meets the American Heart Association's definition of bradycardia. This number alone does not equal a problem. Trained endurance athletes routinely sit at 40 to 50 bpm with no symptoms and no pathology [1].

The clinical question is whether the slow rate produces symptoms: lightheadedness, fatigue, exercise intolerance, near-syncope, or frank syncope. The 2018 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay makes this distinction explicit, stating that "treatment of bradycardia is generally indicated only when symptoms are clearly attributable to the slow heart rate" [2]. A resting rate of 52 bpm in someone who feels fine warrants monitoring, not intervention.

Bradycardia divides into two broad categories based on the origin of the electrical delay. Sinus node dysfunction (sick sinus syndrome) involves the heart's natural pacemaker firing too slowly. Atrioventricular (AV) block involves a delay or complete interruption in the electrical signal between the atria and ventricles. The distinction matters because AV block, particularly third-degree (complete) block, carries a higher risk of sudden hemodynamic compromise [2]. Your physician will determine which category applies based on the ECG pattern.

Why Your Heart Rate Might Be Slow

The causes of bradycardia split cleanly into reversible and structural categories. Identifying a reversible cause first saves patients from unnecessary procedures.

Reversible causes account for the majority of cases seen in primary care. Beta-blockers (metoprolol, atenolol, carvedilol), non-dihydropyridine calcium channel blockers (diltiazem, verapamil), digoxin, and certain antiarrhythmics (amiodarone, sotalol) are the most frequent medication culprits [3]. Hypothyroidism slows the sinus node directly; a 2013 analysis in the Annals of Internal Medicine documented clinically significant bradycardia in approximately 10% of patients with overt hypothyroidism [4]. Electrolyte disturbances (hyperkalemia, severe hypomagnesemia, hypocalcemia) alter cardiac conduction and can produce life-threatening bradyarrhythmias [5]. Obstructive sleep apnea triggers vagal surges during apneic episodes that transiently suppress heart rate, sometimes to below 30 bpm during sleep [6].

Structural causes include age-related fibrosis of the conduction system, infiltrative diseases (amyloidosis, sarcoidosis), post-surgical scarring (particularly after valve surgery), and congenital heart block. These typically require device-based therapy once confirmed [2].

The Standard Lab Panel for Bradycardia

When a patient presents with a slow heart rate, the initial laboratory workup is targeted and efficient. Order these tests before referring to cardiology.

Thyroid-stimulating hormone (TSH): The single most important blood test in the bradycardia workup. The American Thyroid Association recommends TSH measurement in all patients with unexplained bradycardia [7]. A TSH above 10 mIU/L with a low free T4 confirms overt hypothyroidism. Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) can also contribute, though the heart rate effect is smaller [7].

Basic metabolic panel (BMP): Potassium is the priority electrolyte. Hyperkalemia above 6.0 mEq/L directly depresses conduction velocity and can produce sinus bradycardia, AV block, or a sine-wave pattern on ECG [5]. Calcium and magnesium should be checked simultaneously; hypocalcemia prolongs the QT interval and can slow conduction [8].

Digoxin level (if applicable): Digoxin toxicity is a classic cause of bradycardia with a narrow therapeutic window of 0.5 to 0.9 ng/mL for heart failure. Levels above 2.0 ng/mL carry a high risk of bradyarrhythmia, and renal impairment (common in older adults taking digoxin) raises that risk further [9].

Complete blood count and iron studies: Severe anemia does not typically cause bradycardia but can mask it. A patient with a heart rate of 55 bpm and a hemoglobin of 7 g/dL would normally mount a compensatory tachycardia; the absence of that response suggests a conduction system problem [3].

The 12-Lead ECG: What It Tells You

The ECG is the first and most informative test. It is inexpensive, noninvasive, and immediately available. Every patient with a documented heart rate below 60 bpm and symptoms should have one.

Sinus bradycardia shows a normal P-wave before every QRS complex, just at a rate below 60 bpm. This is the most benign pattern. First-degree AV block (PR interval >200 ms) is common, often medication-related, and usually asymptomatic [2]. Second-degree AV block Type I (Wenckebach) shows progressive PR prolongation until a beat drops; it is often benign and associated with high vagal tone. Second-degree Type II (Mobitz II) is more concerning because it can progress without warning to complete heart block. Third-degree (complete) AV block, where atria and ventricles fire independently, almost always requires a pacemaker [2].

The 2018 ACC/AHA/HRS guideline assigns a Class I recommendation (strongest level) for permanent pacing in patients with "symptomatic bradycardia due to sinus node dysfunction" and in patients with "third-degree and advanced second-degree AV block" regardless of symptoms [2]. Dr. Fred Kusumoto, lead author of that guideline, stated: "The decision to implant a pacemaker should always begin with the question of whether the patient's symptoms are clearly related to the documented bradycardia" [2].

Ambulatory Monitoring for Intermittent Symptoms

Not every slow heartbeat is captured during a clinic visit. Intermittent bradycardia requires ambulatory monitoring to establish the diagnosis.

A 24-to-48-hour Holter monitor records every heartbeat continuously. It is best suited for patients with daily or near-daily symptoms. A study published in Heart Rhythm (N=1,540) found that Holter monitoring detected a clinically significant arrhythmia in 15.4% of patients referred for unexplained syncope or presyncope [10].

For less frequent symptoms, a 14-to-30-day event monitor or a patch-based monitor (Zio Patch) provides longer surveillance. The iRhythm Zio Patch, in a 2020 validation study (N=2,661), demonstrated a 57% higher arrhythmia detection rate compared to standard 24-hour Holter monitoring [11].

Implantable loop recorders (ILRs) sit beneath the skin and monitor for up to three years. The PICTURE registry (N=570) showed that ILRs established a definitive diagnosis in 78% of patients with unexplained syncope within 18 months [12]. These are reserved for patients whose symptoms are too infrequent for external monitors to capture.

An exercise stress test can also be revealing. Chronotropic incompetence, defined as failure to reach 80% of the age-predicted maximum heart rate (220 minus age) during maximal exertion, indicates sinus node dysfunction even when resting rates appear borderline [2].

Thyroid Dysfunction and Heart Rate

The thyroid gland exerts direct control over cardiac pacemaker cell firing rate through T3-mediated expression of ion channels, specifically the HCN4 channel responsible for the "funny current" (If) in the sinoatrial node [7].

Overt hypothyroidism (TSH >10 mIU/L, low free T4) produces bradycardia through reduced If current, decreased myocardial contractility, and increased systemic vascular resistance. Treatment with levothyroxine corrects the bradycardia in most patients within 4 to 8 weeks of achieving euthyroid status [7]. A prospective cohort study from the Journal of Clinical Endocrinology & Metabolism (N=324) found that mean heart rate increased from 58.2 bpm to 68.7 bpm after 12 weeks of levothyroxine replacement in patients with overt hypothyroidism [13].

Subclinical hypothyroidism has a less predictable effect. The Cardiovascular Health Study (N=3,233 adults aged 65+) found that participants with TSH between 4.5 and 10 mIU/L had a mean resting heart rate only 2.1 bpm lower than euthyroid controls, a statistically significant but clinically modest difference [14]. Treatment decisions for subclinical hypothyroidism should weigh the full clinical picture, not heart rate alone.

Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient countries. Checking thyroid peroxidase (TPO) antibodies can confirm the autoimmune etiology and guide long-term monitoring expectations [7].

Medication-Induced Bradycardia: The Most Fixable Cause

Medications cause more bradycardia presentations than any other single etiology. A 2019 retrospective study in JAMA Internal Medicine (N=8,232) found that drug-induced bradycardia accounted for 38% of emergency department presentations for symptomatic slow heart rate [15].

Beta-blockers are the most common offenders. Metoprolol, atenolol, propranolol, and carvedilol all suppress sinus node automaticity and AV conduction. The effect is dose-dependent and amplified in patients with pre-existing conduction disease [3]. Reducing the dose or switching to a beta-1-selective agent at a lower dose often resolves the bradycardia without sacrificing the cardiovascular benefit.

Non-dihydropyridine calcium channel blockers (diltiazem and verapamil) slow AV nodal conduction. Combining a beta-blocker with diltiazem or verapamil is a well-documented cause of severe symptomatic bradycardia and is specifically warned against in prescribing guidelines unless done under careful monitoring [3].

Digoxin slows the heart through enhanced vagal tone. Toxicity risk climbs steeply in patients with declining renal function because digoxin is renally cleared. The DIG trial (N=6,800) established the therapeutic window, and subsequent analyses confirmed that serum levels above 1.2 ng/mL are associated with increased mortality in heart failure patients [9].

Amiodarone can cause bradycardia both acutely (through direct suppression of the sinus and AV nodes) and chronically (through amiodarone-induced hypothyroidism, which occurs in 5-10% of treated patients) [3]. Checking TSH every 6 months in patients on amiodarone is standard practice per the American Thyroid Association [7].

The first step in any bradycardia workup: review the medication list. Dr. Sana Al-Khatib, a cardiac electrophysiologist at Duke University and co-author of the 2018 ACC/AHA/HRS bradycardia guideline, has emphasized: "Before considering a pacemaker, every reversible cause must be addressed, and medications are the most common reversible cause we see in practice" [2].

When a Pacemaker Becomes the Answer

Permanent pacemaker implantation is appropriate when symptomatic bradycardia persists after reversible causes have been corrected. Roughly 200,000 pacemakers are implanted annually in the United States [2].

The 2018 ACC/AHA/HRS guideline provides Class I indications (strongest evidence) for permanent pacing in these scenarios [2]:

• Symptomatic sinus node dysfunction with documented bradycardia-symptom correlation
• Third-degree AV block regardless of symptom status
• Advanced second-degree AV block (Mobitz II) with symptoms or with an escape rate below 40 bpm
• Alternating bundle branch block
• Bradycardia-dependent ventricular tachycardia

Modern devices are small. A conventional dual-chamber pacemaker weighs approximately 25 grams and lasts 8 to 12 years on a single battery. Leadless pacemakers (Medtronic Micra, Abbott AVEIR) are implanted directly into the right ventricle via femoral vein catheter, eliminating the need for a surgical pocket and transvenous leads [16]. The Micra Transcatheter Pacing Study (N=725) demonstrated a 48% reduction in major complications compared to conventional transvenous pacemakers at 12 months [16].

Not all bradycardia needs a pacemaker. Athletic sinus bradycardia is physiologic. Nocturnal bradycardia below 40 bpm during sleep can be normal. Drug-induced bradycardia resolves with dose adjustment. Hypothyroid bradycardia resolves with thyroid replacement. The device is the treatment of last resort, not first.

When to Go to the Emergency Department

Certain presentations of bradycardia require immediate evaluation. Do not wait for an outpatient appointment if any of the following are present.

Syncope (full loss of consciousness) associated with a documented or suspected slow heart rate warrants emergency ECG monitoring. The EGSYS score, validated in a cohort of 516 patients presenting with syncope, identifies cardiac syncope with 92% sensitivity when the score is 3 or higher [17].

Heart rate below 40 bpm with symptoms (dizziness, confusion, chest pain, or shortness of breath) suggests hemodynamically significant bradycardia. Intravenous atropine 0.5 mg is the first-line treatment per ACLS guidelines, with transcutaneous pacing as a bridge if atropine fails [18].

New-onset complete heart block on ECG, even in an asymptomatic patient, requires hospital admission for monitoring and probable pacemaker implantation. The escape rhythm in complete heart block is unreliable and can degenerate without warning [2].

Hyperkalemia with ECG changes (peaked T waves, widened QRS, loss of P waves) is a medical emergency. Treatment includes intravenous calcium gluconate for membrane stabilization, insulin with dextrose, and sodium bicarbonate, followed by definitive potassium lowering [5].

If you have a documented heart rate below 50 bpm and you are experiencing lightheadedness, near-fainting, or fainting episodes, bring a written list of all medications (including over-the-counter supplements) and any home heart rate readings from a wearable device to your evaluation. The initial blood panel should include TSH, BMP (with potassium, calcium, magnesium), and digoxin level if you take that drug, alongside a 12-lead ECG recorded within minutes of arrival.